Skip to main content

Drug Updates

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Updates
Web Exclusives
In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia. Read More ›
Defitelio (Defibrotide Sodium): FDA Approved for Patients with Hepatic Veno-Occlusive Disease
By E. K. Charles, MBS
Drug Updates
TOP - May 2016, Vol 9, No 2
This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT. Read More ›
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Updates
TOP - February 2016, Vol 9, No 1
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Read More ›
FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery
Drug Updates
Web Exclusives
Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner. Read More ›
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Updates
TOP November 2015 Vol 8 No 4
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015. Read More ›
Off-Label Drug Use Accounts for 18% of Spending
By Caroline Helwick
Drug Updates
TOP - October 2013 VOL 6, NO 4
An examination of the Sur-veillance, Epidemiology and End Results (SEER)-Medicare database from 1998 through 2008 revealed that a significant number of patients with cancer received unapproved drugs... Read More ›
Surveys Confirm Drug Shortages Are a Persistent Problem
By Caroline Helwick
Drug Updates
TOP - October 2013 VOL 6, NO 4
Recent surveys of oncologists and hematologists show that drug shortages persist, that practitioners are adapting in ways that often raise the cost of cancer care, and that most have no guidance to aid in decision making in the face of these shortages. Read More ›
Safety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Drug Updates
Faculty Perspectives May 2013 Vol 4 No 3
This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety Read More ›
Toxicity of Bendamustine Therapy
By Susanne Liewer, PharmD, BCOP
Drug Updates
Faculty Perspectives May 2013 Vol 4 No 3
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). Read More ›

Page 2 of 3